Drug delivery to macrophages: a review of nano-therapeutics targeted approach for inflammatory disorders and cancer

Mukhtar, Mahwash; Ali, Hussain; Ahmed, Naveed; Munir, Rashid; Talib, Sumbal; Khan, Anam; Ambrus, Rita

doi:10.1080/17425247.2020.1783237

Cited by 40 publications

(24 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Macrophages are major cell types in atherosclerotic plaque, so targeting macrophages is a potential strategy for treating atherosclerotic lesions locally ( Table 3 ). Macrophages express various protein receptors, some of which can be used as potential therapeutic targets, such as the mannose receptor, macrophage scavenger receptor (SR), CD44 receptor and folate receptor [ 103 ] ( Fig. 4 ).…”

Section: Targeting Macrophages For Drug Deliverymentioning

confidence: 99%

Tuning macrophages for atherosclerosis treatment

Fang

Xiao

et al. 2022

Regenerative Biomaterials

View full text Add to dashboard Cite

Atherosclerosis is a chronic inflammatory vascular disease and one of the leading causes of death worldwide. Macrophages play an important role in atherosclerosis in the inflammatory response, cell-cell communications, plaque growth, and plaque rupture in atherosclerotic lesions. Here we review the sources, functions, and complex phenotypes of macrophages in the progression of atherosclerotic, and discuss the recent approaches in modulating macrophage autophagy and phenotypic transformation for atherosclerosis treatment. We then focus on the drug delivery strategies that target macrophages or use macrophage membrane-coated particles to deliver therapeutics to the lesion sites. These biomaterial-based approaches to target, modulate, or engineer macrophages have broad applications for disease therapies and tissue regeneration.

show abstract

Section: Targeting Macrophages For Drug Deliverymentioning

confidence: 99%

Tuning macrophages for atherosclerosis treatment

Fang

Xiao

et al. 2022

Regenerative Biomaterials

View full text Add to dashboard Cite

show abstract

“…Macrophages linked with tumors are known as TAMs and are classified into two phenotypes-M1 and M2 (M1 type TAMs suppress cancer progression, while M2 type TAMs promote it). TAMs are characterized by increased M2/M1 ratio and play a crucial role in tumor progression, metastasis, matrix remodeling, angiogenesis and tumor resistance [105,106]. TAMs produce cytokines, growth factors like epithelial growth factor, matrix metalloproteinase-9, angiopoietin, etc.…”

Section: Tumor-associated Macrophages (Tams)mentioning

confidence: 99%

Onco-Receptors Targeting in Lung Cancer via Application of Surface-Modified and Hybrid Nanoparticles: A Cross-Disciplinary Review

et al. 2021

View full text Add to dashboard Cite

Lung cancer is among the most prevalent and leading causes of death worldwide. The major reason for high mortality is the late diagnosis of the disease, and in most cases, lung cancer is diagnosed at fourth stage in which the cancer has metastasized to almost all vital organs. The other reason for higher mortality is the uptake of the chemotherapeutic agents by the healthy cells, which in turn increases the chances of cytotoxicity to the healthy body cells. The complex pathophysiology of lung cancer provides various pathways to target the cancerous cells. In this regard, upregulated onco-receptors on the cell surface of tumor including epidermal growth factor receptor (EGFR), integrins, transferrin receptor (TFR), folate receptor (FR), cluster of differentiation 44 (CD44) receptor, etc. could be exploited for the inhibition of pathways and tumor-specific drug targeting. Further, cancer borne immunological targets like T-lymphocytes, myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), and dendritic cells could serve as a target site to modulate tumor activity through targeting various surface-expressed receptors or interfering with immune cell-specific pathways. Hence, novel approaches are required for both the diagnosis and treatment of lung cancers. In this context, several researchers have employed various targeted delivery approaches to overcome the problems allied with the conventional diagnosis of and therapy methods used against lung cancer. Nanoparticles are cell nonspecific in biological systems, and may cause unwanted deleterious effects in the body. Therefore, nanodrug delivery systems (NDDSs) need further advancement to overcome the problem of toxicity in the treatment of lung cancer. Moreover, the route of nanomedicines’ delivery to lungs plays a vital role in localizing the drug concentration to target the lung cancer. Surface-modified nanoparticles and hybrid nanoparticles have a wide range of applications in the field of theranostics. This cross-disciplinary review summarizes the current knowledge of the pathways implicated in the different classes of lung cancer with an emphasis on the clinical implications of the increasing number of actionable molecular targets. Furthermore, it focuses specifically on the significance and emerging role of surface functionalized and hybrid nanomaterials as drug delivery systems through citing recent examples targeted at lung cancer treatment.

show abstract

“…In addition to it, fabrication of lipid-based nanoparticles with an optimal size distribution, giving shelter from rapid clearance and providing more resident time at the target site are complex and extremely challenging (Ref. 80). Thus, it is mandatory to determine the biological behaviours (size, shape, surface properties) of such therapeutics in physiological environment.…”

Section: Comprehensive Summary Of Challenges and Their Possible Solutionsmentioning

confidence: 99%

Biomacromolecule-mediated pulmonary delivery of siRNA and anti-sense oligos: challenges and possible solutions

Hussain

Cui

Khan

et al. 2021

Expert Rev. Mol. Med.

View full text Add to dashboard Cite

Biomacromolecules have gained much attention as biomedicine carriers in recent years due to their remarkable biophysical and biochemical properties including sustainability, non-toxicity, biocompatibility, biodegradability, long systemic circulation time and ability to target. Recent developments in a variety of biological functions of biomacromolecules and progress in the study of biological drug carriers suggest that these carriers may have advantages over carriers of synthetic materials in terms of half-life, durability, protection and manufacturing facility. Despite the full pledge advancements in the applications of biomacromolecules, its clinical use is hindered by certain factors that allow the pre-mature release of loaded cargos before reaching the target site. The delivery therapeutics are degraded by systemic nucleases, cleared by reticulo-endothelial system, cleared by pulmonary mucus cilia or engulfed by lysosome during cellular uptake that has led to the failure of clinical therapy. It clearly indicates that there is a wide range of gaps in the results of experimental work and clinical applications of biomacromolecules. This review focuses mainly on the barriers (intracellular/extracellular) and hurdles to the delivery of biomacromolecules with special emphasis on siRNA as well as the delivery of antisense oligos in multiple pulmonary diseases, particularly focusing on lung cancer. Also, the challenges posed to such delivery and possible solutions have been highlighted.

show abstract

Drug delivery to macrophages: a review of nano-therapeutics targeted approach for inflammatory disorders and cancer

Cited by 40 publications

References 110 publications

Tuning macrophages for atherosclerosis treatment

Tuning macrophages for atherosclerosis treatment

Onco-Receptors Targeting in Lung Cancer via Application of Surface-Modified and Hybrid Nanoparticles: A Cross-Disciplinary Review

Biomacromolecule-mediated pulmonary delivery of siRNA and anti-sense oligos: challenges and possible solutions

Contact Info

Product

Resources

About